Biohaven is a modern pharmaceutical company that is guided by science and inspired to change the lives of people with unmet medical needs.
New Haven, CT
- Tweets 1,170
- Following 846
- Followers 2,215
- Likes 3,439
We’re looking forward to the conversations at this year’s ABI Sweden Conference! Our Chief Translational Officer will moderate a panel bringing together industry leaders to discuss the next generation of autoimmune medicines.
#DaysMatter
#ABI26
ALT ABI Conference
1
85
The Biohaven team is headed to Athens and looking forward to sharing new research through both an oral presentation and a poster presentation at the @IlaeWeb European Epilepsy Congress.
#EEC2026
#DaysMatter
#Epilepsy
#Neurology
ALT International League Against Epilepsy Europe, Epilepsy Congress
3
163
Today, we announced a strategic global licensing and collaboration agreement with SK Biopharmaceuticals, the parent company of @SKLifeScience, focused on advancing our Kv7 platform and opakalim, our lead candidate in development for focal epilepsy.
Read the full announcement: bit.ly/4hQAU5i
3
234
In her latest LinkedIn article, our Executive Director of Clinical Operations at Biohaven, reflects on more than two decades in drug development and the lessons she's learned about resilience, collaboration and trusting the scientific process.
Read more: brnw.ch/21x4wiC
1
3
219
At #ESMO2026, our team will present new data from our investigational BHV-1530 program, highlighting our continued commitment to advancing innovative approaches in oncology. We look forward to sharing our latest research with the global cancer community. brnw.ch/21x4j3X
ALT Biohaven to present new clinical data at ESMO
2
273
We’re pleased to share that our Executive Vice President and Head of Drug Discovery will host a workshop at the Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit next week in Boston. Learn more: bit.ly/4vtGKh0
#DaysMatter
2
165
What excites investigators about BHV-1300? Innovation and the potential to advance Graves’ disease treatment with a targeted, mechanism-based approach. Learn more about our Graves' disease clinical trial: brnw.ch/21x3JKc
#DaysMatter
3
207
In the news: @Neurology_Live featured our Chief Medical Officer discussing the latest data from our investigational epilepsy program and the ongoing need for new treatment options. Read the full feature below.
brnw.ch/21x3zMr
#DaysMatter
#Epilepsy
1
2
306
Biohaven retweeted
What sets opakalim apart from earlier Kv7 therapies? No off-target GABA potentiation, and that may be the key to its cleaner CNS tolerability profile.
@biohaven CMO Irfan Qureshi, MD breaks it down in a new Q&A🔬👇
neurologylive.com/view/irfan…
1
2
224
It was great connecting with the nephrology community at the @ERAkidney Congress in Glasgow.
Thank you to everyone who stopped by our booth to learn more about our TRAP™ degrader and shared meaningful conversations with our team. See you next year!
#ERA26
ALT ERA Congress in Glasgow, Scotland
1
171
Our Chief Translational Officer will be speaking at the @GoldmanSachs Annual Global Healthcare Conference, sharing insights on our pipeline developments.
#DaysMatter
#Innovation
#Pipeline
2
135
We’re excited to be part of the important conversations happening in metabolic health at @ADA_DiabetesPro. These discussions are critical to advance a deeper understanding of the complexity of obesity, and to drive scientific progress forward.
#ADASciSessions
#MedEd
1
167
Our annual Research & Development Day brought together our leadership team, industry experts and investors to share the latest on Biohaven’s pipeline progress in immunology, epilepsy, obesity and more. View the presentation here: brnw.ch/21x344H
#DaysMatter
#Investors
ALT Biohaven’s R&D Day
1
4
164
Biohaven is heading to the @ERAkidney Congress with a booth highlighting our TRAP™ degrader. Come stop by, say hello to our team and learn more about our work in kidney disease: brnw.ch/21x324Y
#ERA26
#DaysMatter
#IgAN
#KidneyDisease
#MedEd
ALT ERA Congress
1
192
Connecticut innovation was front and center at the Yale Innovation Summit! Our CEO joined healthcare leaders for a panel discussion on building and scaling companies within Connecticut’s growing biotech ecosystem.
#YaleInnovationSummit
#Connecticut
#Biotech
#DaysMatter
ALT Yale Innovation Summit
1
139
We look forward to connecting with peers across the ecosystem at the Yale Innovation Summit and advancing conversations that help bring new scientific breakthroughs closer to patients. Join us: brnw.ch/21x2PV6
#YaleInnovationSummit
#Biotech
#Innovation
1
125
Purpose and empathy help drive scientific innovation. Shodeinde Coker, M.D. shares his oncology journey and commitment to advancing new treatments for people facing cancer. Read more: brnw.ch/21x2CMk #DaysMatter #Oncology #ADCs
1
125
Biohaven is featured in the news for our differentiated approach to obesity treatment — one focused not just on weight loss, but on improving body composition by targeting fat reduction while building muscle. Read more about our experimental program: brnw.ch/21x2sdG
ALT Peter Ackerman, MD, featured in PharmaVoice
1
3
185
#Investors: Our Chief Medical Officer and SVP of Finance will participate in a fireside chat at the Bank of America Global Healthcare Conference, sharing insights on our pipeline developments.
#DaysMatter
#Innovation
#Pipeline
ALT Bank of America Global Healthcare Conference
4
152
In his recent article, Brian McGuire, M.D., shares how his experience in emergency medicine continues to shape his work in drug development and his commitment to helping patients. Read more: brnw.ch/21x20Eg
#ThoughtLeadership
#DaysMatter
#PrecisionMedicine
2
218